Artiva Biotherapeutics (NASDAQ:ARTV) Downgraded by Wedbush to “Neutral”

Artiva Biotherapeutics (NASDAQ:ARTV) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. They currently have a $4.00 price target on the stock. Wedbush‘s price target indicates a potential downside of 5.55% from the company’s previous close.

Several other research analysts also recently commented on ARTV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Monday, October 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. Finally, Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $30.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV traded down $1.93 during mid-day trading on Tuesday, hitting $4.24. The stock had a trading volume of 5,924,527 shares, compared to its average volume of 421,593. Artiva Biotherapeutics has a 1 year low of $2.96 and a 1 year high of $14.53. The business has a 50 day moving average price of $8.80 and a two-hundred day moving average price of $7.96. The firm has a market cap of $207.05 million, a P/E ratio of -1.28 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). Equities research analysts predict that Artiva Biotherapeutics will post -2.62 EPS for the current fiscal year.

Insider Buying and Selling at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, COO Jennifer Bush sold 8,370 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total transaction of $57,250.80. Following the transaction, the chief operating officer directly owned 366,159 shares of the company’s stock, valued at approximately $2,504,527.56. The trade was a 2.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ra Capital Management, L.P. acquired 24,944 shares of Artiva Biotherapeutics stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $9.93 per share, for a total transaction of $247,693.92. Following the completion of the transaction, the director owned 17,329,570 shares in the company, valued at approximately $172,082,630.10. This trade represents a 0.14% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders sold 137,048 shares of company stock worth $1,086,167. 1.80% of the stock is owned by corporate insiders.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARTV. BlackRock Inc. purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $6,739,000. Nantahala Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $2,910,000. ADAR1 Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $1,151,000. Alyeska Investment Group L.P. grew its holdings in Artiva Biotherapeutics by 173.6% in the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after purchasing an additional 173,615 shares during the period. Finally, Blue Owl Capital Holdings LP purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $8,483,000.

Key Artiva Biotherapeutics News

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported approximately $319.1 million in cash, cash equivalents and investments as of September 30, 2026, providing financial resources while it evaluates strategic alternatives. Leerink Partners has been hired as financial adviser. Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK
• Neutral Sentiment: Trading in ARTV was temporarily halted for news before the strategic update was released, increasing volatility and limiting trading during the announcement.
• Negative Sentiment: The company cited two recent Grade 5 safety events, including a case of leukoencephalopathy assessed as likely related to fludarabine toxicity and another event assessed as unrelated to the study treatment. Reports describe the events as two patient deaths. Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%
• Negative Sentiment: Although updated data continued to show B-cell depletion and clinical responses, longer-term follow-up indicated that response durability did not meet Artiva’s threshold for continued development. Ending the lead program removes the company’s primary clinical catalyst and commercial opportunity.
• Negative Sentiment: Artiva plans to reduce its workforce by approximately 94% as it explores strategic options, signaling a major contraction of operations and uncertainty about the company’s future as an independent developer. Artiva Biotherapeutics stock tumbles after halting drug trial
• Negative Sentiment: Analysts reacted negatively: Needham cut its rating from Buy to Hold, while Wedbush downgraded the stock from Outperform to Neutral and set a $4.00 price target. Artiva Biotherapeutics Ends AlloNK Program, Explores Strategic Options

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.